G. Laustsen
Jul 1, 2005
Citations
0
Influential Citations
0
Citations
Journal
The Nurse practitioner
Abstract
Pramlintide acetate (Symlin) is a new antihyperglycemic drug that was approved by the Food and Drug Administration (FDA) for use in adult diabetic patients currently treated with insulin. Amylin Pharmaceuticals developed the drug after 18 years of research into the pathophysiology and treatment of diabetes. The primary therapeutic effect of pramlintide is to improve postprandial glucose control in diabetics using insulin. The drug also induces patient satiety, leading to potential weight loss by reducing caloric intake.